ArticleCancer medicine2021

Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.

Hui-Jen Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.